SCHEMBL1040530

SCHEMBL1040530

Cc1ccc(P(c2ccc(C)cc2)c2ccc3c(c2-c2c(P(c4ccc(C)cc4)c4ccc(C)cc4)ccc4c2CCCC4)CCCC3)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 6/20 0.40
ALDH1A1 P00352 2/20 0.38
DPP4 P27487 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
PARP1 P09874 1/20 0.33
LMNA P02545 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
MAPT P10636 1/20 0.32
NFKB1 P19838 1/20 0.32
RAB9A P51151 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
THRB P10828 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PSIP1 O75475 1/20 0.31
BCL2L1 Q07817 1/20 0.31
BAD Q92934 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1044167 0.87 MEN1 (0.43) CES1ALDH1A1MEN1KMT2APARP1
SCHEMBL31438411 0.87 MEN1 (0.43) CES1ALDH1A1MEN1KMT2APARP1
SCHEMBL1082547 0.83 KDM4E (0.38) CES1ALDH1A1PARP1LMNAKDM4E
SCHEMBL29924184 0.83 DRD1 (0.39) CES1PARP1BCL2L1BAD
SCHEMBL665033 0.83 DRD1 (0.39) CES1PARP1BCL2L1BAD
SCHEMBL29424782 0.83 DRD1 (0.39) CES1PARP1BCL2L1BAD
SCHEMBL1042360 0.83 CES1 (0.37) CES1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL2003369 0.83 CES1 (0.34) CES1ALDH1A1PARP1LMNASMN1; SMN2
SCHEMBL31566360 0.83 CES1 (0.37) CES1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL2011321 0.83 ALDH1A1 (0.35) CES1ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2981560-B1 CURING OF LIQUID THERMOSETTING RESINS REICHHOLD LLC 2 (US) 2021-10-13 EP claimed
US-9068045-B2 Curing of liquid thermosetting resins REICHHOLD, INC. (US) 2015-06-30 US claimed
US-20140303315-A1 CURING OF LIQUID THERMOSETTING RESINS Polynt Composites USA Inc. 2014-10-09 US claimed
EP-1650207-B1 Process for producing optically active 3-quinuclidinols TAKASAGO PERFUMERY CO LTD (JP) 2007-06-27 EP claimed
WO-2025096445-A1 SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF MACROCYCLIC COMPOUNDS ALKERMES, INC. (US) 2025-05-08 WO disclosed
US-12071498-B2 Radically polymerizable compositions Polynt Composites USA, Inc. (US) 2024-08-27 US disclosed
US-20230257500-A1 RADICALLY POLYMERIZABLE COMPOSITIONS BNY MELLON CORPORATE TRUSTEE SERVICES LIMITED, AS SECURITY AGENT (GB) 2023-08-17 US disclosed
US-11518834-B2 Radically polymerizable compositions Polynt Composites USA, Inc. (US) 2022-12-06 US disclosed
US-20220169600-A1 METHOD FOR PRODUCING PKROSTAGLANDIN KYOWA PHARMA CHEMICAL CO., LTD. (JP) 2022-06-02 US disclosed
EP-3950672-A1 METHOD FOR PRODUCING PKROSTAGLANDIN Kyowa Pharma Chemical Co., Ltd. (JP) 2022-02-09 EP disclosed
EP-3906265-A1 RADICALLY POLYMERIZABLE COMPOSITIONS Polynt Composites USA Inc. (US) 2021-11-10 EP disclosed
EP-2981560-B1 CURING OF LIQUID THERMOSETTING RESINS REICHHOLD LLC 2 (US) 2021-10-13 EP disclosed
US-6342644-B1 MULTISTAGE PROCESS OF HYDROGENATION WITH PHOSPHINE COMPLEX TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-01-29 US disclosed
US-20020007094-A1 Method for producing 1-menthol TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-01-17 US disclosed
EP-1153908-A2 Method for producing 1-menthol Takasago International Corporation (JP) 2001-11-14 EP disclosed
EP-0673911-B1 Process for producing optically active carboxylic acids and chiral ligands for this purpose TAKASAGO PERFUMERY CO LTD (JP) 1999-01-20 EP disclosed
EP-0781749-A2 Process for producing optically active benzhydrol compounds Takasago International Corporation (JP) 1997-07-02 EP disclosed
US-5587510-A ASYMMETRICAL HYDROGENATION USING RUTHENIUM-PHOPSHINE COMPLEX AS CATALYSTS TAKASAGO INTERNATIONAL CORPORATION (JP) 1996-12-24 US disclosed
US-5563295-A HYDROGENATION OF OLEFINIC CARBOXYLIC ACID USING RUTHENIUM-PHOSPHINE COMPLEX CATALYST TAKASAGO INTERNATIONAL CORPORATION (JP) 1996-10-08 US disclosed
EP-0673911-A1 Process for producing optically active carboxylic acids and chiral ligands for this purpose Takasago International Corporation (JP) 1995-09-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169600-A1 METHOD FOR PRODUCING PKROSTAGLANDIN PTGS1, PTGER1, RACK1 CES1 1327/4885ALDH1A1 1425/4885DPP4 4532/4885
US-20020007094-A1 Method for producing 1-menthol HRH4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PHOSPHO1 CES1 2700/4885ALDH1A1 1768/4885DPP4 4143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.